The abstract is read at the publisher; the summary is JClub's.
In 224 treatment-naive nAMD eyes, AI-based OCT showed higher week-12 dry macula rates with faricimab (80.3%) and aflibercept 2 mg (67.9%) than bevacizumab (41.3%).
- Why it matters: Short-term anatomic response after anti-VEGF loading is clinically important, but comparative OCT-based characterization across agents remains limited, especially using automated measures.
- What they did: This multicenter retrospective cohort compared three monthly intravitreal injections of bevacizumab, aflibercept 2 mg, or faricimab, using AI OCT segmentation of IRFv and SRFv at baseline and week 12. An exploratory ΔCOMBO metric was tested with receiver operating characteristic analysis.
- The result: All three agents improved BCVA and OCT parameters by week 12, with BCVA gains significant for bevacizumab and faricimab, while baseline-adjusted OCT differences appeared across treatments. ΔCOMBO discriminated dry macula with AUC 0.959 (95% CI, 0.907-0.999), suggesting AI biomarkers may characterize short-term anatomic response but need external validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.